S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Impax Pharmaceuticals Announce FDA Approval of RYTARY™ (Carbidopa and Levodopa) Extended-Release Capsules for the Treatment of Parkinson's disease (2015/1/8)|
|Impax Revenues Increased 30% to $131 Million in Fourth Quarter 2014 (2015/2/24)|
|Impax to Present at the 33rd Annual J.P. Morgan Healthcare Conference (2015/1/6)|
|Impax to Report Fourth Quarter 2014 Results on February 24, 2015 (2015/1/29)|
|Impax Receives FDA Approval for a Generic Version of Lamictal® Orally Disintegrating Tablets (ODT) (2015/1/26)|
|Impax to Present at the Cowen and Company 35th Annual Health Care Conference (2015/2/25)|
|UPDATE: Charting a sluggish, but bullish, S&P 500 breakout attempt (2015/2/17)|
|Charting a sluggish, but bullish, S&P 500 breakout attempt (2015/2/17)|
|S&P 500's slow-motion breakout attempt remains in play (2015/2/10)|
|S&P 500 plunges from major resistance (2015/1/27)|
Click above to view more mutual fund data and stats for ipxl - Impax Laboratories Inc.